Pharmacotherapy and Intensive Treatment - 2

This study has been completed.
Sponsor:
Collaborator:
Information provided by:
National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:
NCT00000218
First received: September 20, 1999
Last updated: March 23, 2009
Last verified: March 2009
  Purpose

The purpose of this study is to evaluate desipramine and carbamazepine in reducing cocaine craving; increase outpatient treatment capacity and evaluate their incidence of psychiatric disorders.


Condition Intervention Phase
Cocaine-Related Disorders
Substance-Related Disorders
Drug: Carbamazepine
Phase 4

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Pharmacotherapy and Intensive Treatment

Resource links provided by NLM:


Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:
  • Severity addiction
  • Depression
  • Depression, anxiety

Estimated Enrollment: 353
Study Completion Date: June 2005
  Eligibility

Ages Eligible for Study:   18 Years to 60 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Please contact site for information.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000218

Locations
United States, Missouri
University of Kansas
Kansas City, Missouri, United States, 64128
Sponsors and Collaborators
Investigators
Principal Investigator: William Haning, M.D. University of Kansas
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00000218     History of Changes
Other Study ID Numbers: NIDA-06954-2, R18-06954-2
Study First Received: September 20, 1999
Last Updated: March 23, 2009
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Cocaine-Related Disorders
Substance-Related Disorders
Disease
Chemically-Induced Disorders
Mental Disorders
Pathologic Processes
Carbamazepine
Anticonvulsants
Central Nervous System Agents
Therapeutic Uses
Pharmacologic Actions
Antimanic Agents
Tranquilizing Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Psychotropic Drugs
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents

ClinicalTrials.gov processed this record on September 16, 2014